Xueting He

Xueting He

Auto-generated profile, based on publicly available information

Xueting He

Jacobio Pharmaceuticals Co., Ltd., Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Clinical studies have demonstrated the antitumor efficacy of covalent KRAS G12C inhibitors in treating advanced/metastatic cancers. In the current study, we report the preclinical characteristics of a specific KRAS p.G12C covalent inhibitor, glecirasib. Glecirasib exhibited high potency against KRAS G12C, along with a high level of selectivity over wild-type KRAS, HRAS, and NRAS in biochemical assays. On the cellular level, it substantially reduced downstream ERK and AKT phosphorylation, inhibited the viability of cancer cells harboring the KRAS p.G12C mutation, and demonstrated high selectivity over non-KRAS p.G12C cancer cells. Glecirasib could effectively inhibit HRAS G12C, NRAS G12C, and several G12C-inclusive KRAS double mutants that showed resistance to adagrasib. In vivo research suggested that once-daily dosing of glecirasib can robustly inhibit ERK phosphorylation for at least 24 hours and induced tumor regression in several xenograft models, including the NCI-H1373–luciferase intracranial model. Glecirasib in combination with cetuximab or JAB-3312 (sitneprotafib, a clinical-stage SHP2 inhibitor developed by Jacobio Pharma) significantly enhanced antitumor activity both in vitro and in vivo. Collectively, these results suggest that glecirasib is a potent and selective covalent inhibitor of KRAS G12C, shows potent antitumor activity as monotherapy, and synergizes with either EGFR blockade or SHP2 inhibition. A new drug application for glecirasib has been submitted in China, seeking approval for the treatment of non–small cell lung cancer, supported by a pivotal phase II single-arm study (NCT05009329). Additionally, glecirasib is being explored in clinical trials in combination with cetuximab (phase II, NCT05194995) and JAB-3312 (phase III, NCT06416410). Significance: Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C–mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C–mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

15 May 2025
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S6 shows IC50 values in GppNp-bound RAS and cRAF interaction assays.

15 May 2025
Verified
Other
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Glecirasib inhibited ERK phosphorylation and growth of tumors carrying the KRAS G12C mutation in vivo. A–C, PK/PD studies of a single-dose glecirasib administration in NCI-H358 lung cancer xenograft tumors bearing in the flank of mice. Dose response following a single dose of glecirasib is shown in A. Time-dependent PK/PD properties after a single dose of 30 mg/kg and 100 mg/kg glecirasib are shown in B and C, respectively. After 8 hours, glecirasib concentrations in both plasma and tumor in the 30 mg/kg group, as well as the plasma drug concentration in the 100 mg/kg group, were below the quantification limit (plasma: 1 ng/mL; tumor: 5.5 ng/g). Glecirasib concentrations in plasma and tumor tissue were quantified by LC/MS-MS, whereas p-ERK levels in tumors were measured by HTRF. Three mice per group. D–F,In vivo efficacy studies of glecirasib in CDX models: NCI-H1373 lung cancer (D), NCI-H358 lung cancer (E), and MIA PaCa-2 pancreatic cancer (F). NCI-H1373 and MIA PaCa-2 CDX models: six mice per group; NCI-H358 CDX model: eight mice per group. Glecirasib was administrated once a day orally. G and H, Tumor growth curves (G) and mice body weight curves (H) of the LUN156 lung cancer PDX model after treatment with glecirasib. Six mice per group. All data are represented as the mean ± SEM. conc., concentration; p.o., orally; QD, once a day.

15 May 2025
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S2 shows assay conditions of GppNp-RAS and cRAF interaction assays.

16 March 2026
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S10 shows the data of in vitro safety panel screening.

15 May 2025
Verified
Other
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Glecirasib in combination with the SHP2 inhibitor JAB-3312 synergistically inhibited cancer cell growth. A, Cell viability (2D) dose–response map and Loewe synergy map of glecirasib in combination with JAB-3312 on the indicated cancer cell lines (n = 2), with darker blue colors denoting greater cell viability inhibition and deeper red colors demonstrating stronger Loewe synergistic effect. Global Loewe synergy scores are indicated at the top of Loewe synergy maps. Global Loewe synergy score >5 indicates synergistic effect. B and C, Inhibition of p-ERK (B) and p-AKT (C) by either glecirasib, JAB-3312, or combinations in SW837 and SW1463 (n = 2). The CI for the 50% effect (CI50) was indicated, and CI50 < 0.9 indicates synergistic effect. D, Glecirasib and JAB-3312 combination studies in the NCI-H1373 lung cancer xenograft model. Six mice per group. *, P < 0.05 vs. combination group. All data are shown as the mean ± SEM. conc., concentration; p.o., orally; QD, once a day.